Arcutis Biotherapeutics, Inc. (ARQT)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $3.19B
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: October 27, 2026
Profit #1320 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | -1.7% | -14.0% | -20.0% | -35.2% |
Growth #8 of 1484 companies
Payout #1117 of 1484 companies
Safety #1268 of 1484 companies
Price #1251 of 1484 companies
